MAQS Advokatbyrå advised QuiaPEG Pharmaceuticals on the deal.
QuiaPEG Pharmaceuticals Holding AB (publ) has carried out a fully guaranteed issue of units consisting of shares, warrants of series TO6 and warrants of series TO7 with preferential rights for existing shareholders of initially approximately SEK 28.4 million. In connection therewith, a prospectus has been prepared which has been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen).
Uppsala-based QuiaPEG Pharmaceuticals Holding AB is a drug development company based on a patented drug delivery platform, Uni-Qleaver®. The company is developing improved and patentable forms of medicines under development, or which have already been approved by the pharmaceutical authorities. These refined and better forms of pharmaceuticals are based on the company’s patented technology platform.
The company is listed on the Nasdaq First North Growth Market.
The MAQS Advokatbyrå team consisted Eric Ehrencrona (Picture), Anders Eriksson and Fredrik Brusberg.
Clients: QuiaPEG Pharmaceuticals Holding AB;